Insights & news

Van Bael & Bellis successfully represents cable operators Nethys and Brutélé in proceedings against regulated wholesale tariffs for access to cable networks

  • 06/11/2017
  • News

On 25 October 2017, in four separate judgments, the Brussels Court of Appeal annulled two sets of decisions adopted in 2013 and 2016 by the Belgian telecommunications regulators. These decisions determine the wholesale tariffs applicable to the access to, and use of, cable operators’ networks by their competitors, such as Orange Belgium.

The four judgments are significant as they annul with retroactive effect all of the tariff rules imposed by the telecommunications regulators following the opening of the cable networks in Belgium in 2011.

More specifically, the Court found that the 2013 decisions lacked adequate reasons as the Belgian regulators had ignored the European Commission’s opinion on the draft decisions without explaining why they chose not to follow it. The Court also found fault with the regulators’ approach to consider Nethys and Brutélé as a single cable operator. Finally, the Court held that the 2016 decisions were also invalid as they relied on the annulled decisions of 2013 and were, in addition, based on an outdated analysis of the broadcasting market in breach of EU telecommunications law.

Van Bael & Bellis partner Peter L’Ecluse and associates Valérie Lefever, Eléonore Waterkeyn and Quentin Declève represented cable operators Nethys and Brutélé.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 19/02/2019
    • Newsletters

    VBB on Belgian Business Law, Volume 2019, No. 01

    The January 2019 issue of our Belgian Business Law newsletter reporting on the latest developments in a range of areas, including competition, data protection, intellectual property and labour law. Please click below to read the issue.

    Read more
    • 18/02/2019
    • Articles

    Belgium - Bill regarding Reimbursement of Pharmaceutical Specialties

    On 7 February 2019, the federal government submitted a bill regarding the reimbursement of pharmaceutical specialties to the federal chamber of representatives (Bill 54 3535/001) (the “Bill”). The Bill provides for the following saving measures designed to contain the pharmaceutical budget: • More significant price decrease on the basis of turnover for medicines that have benefited from reimbursement for 15 years (“volume cliff”) (There will be a staggered system providing for a range of turnover figures between EUR 1.5 million and EUR 70 million). • Extension of maximum price (“ceiling price”) system from medicines delivered in the community pharmacy to medicines delivered in the hospital pharmacy. • Start of cheapest prescriptions and prescription quota systems in hospital environment. • Further limitation of invoicing level open to hospitals to 85% of the official price. This system applies to a segment of the medicines open to competition, namely medicines falling under the reference reimbursement system. It is designed to channel to the public purse part of the savings made by hospitals from discounts obtained from their suppliers. • Adaptation of definition of “cheap prescription”. • Medicines in reimbursement category F will now also be made subject to the price cuts applying to “old” medicines (reimbursed for 12 or 15 years). The reimbursement basis of medicines of category F is a flat fee per indication, treatment or analysis. • Definition of specific compensating levy for 2019 (“compenserende heffing”/”cotisation compensatoire”). • Limited increase of pricing transparency for medicines subject to Managed Entry Agreements: Members of the General Council (the top body within the Public Institute for Illness and Disability Insurance) and of the Auditing Court (which verifies and oversees the spending of the government) will be given access to aggregated price information (as a rule on the ATC1 level, i.e., the top level of the Anatomical Therapeutic Chemical Classification System of medicines). The qualifying members will be required to sign a non-disclosure agreement. The government is apparently confident that the Bill will garner a majority in the chamber. The Bill can be found here:

    Read more
    • 14/02/2019
    • Articles

    Overview of the EU’s Single-Use Plastics Directive

    This client alert provides an overview of the EU’s forthcoming “Directive on the reduction of the impact of certain plastic products on the environment”, otherwise known as the single-use plastics Directive. The Directive is expected to enter into force in late spring or early summer 2019 and will have a major impact on the future of the EU plastics market. It is important for both traders and manufacturers to understand how their businesses may be affected as the requirements of the Directive are phased in over the next two to five years.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *